Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigious | ||
Readability |
H.S. sophomore Avg
|
New words:
alter, arbitration, asserted, assigned, assistance, Cambridge, CGI, charitable, classification, compendia, conversion, CRC, criterion, Dastgheib, death, delegate, deliverable, derecognition, diagnosed, difficulty, disability, exact, exposed, fluoropyrimidine, footing, forfeited, frequency, GenMab, infusion, Inotek, Institute, larger, longest, mark, match, modest, monthly, Nonqualified, PARP, poly, polymerase, proceed, pursue, receipt, rental, resubmit, shown, slightly, switched, tenant, Vectibix
Removed:
chemical, CMS, Modernization, priority, shift
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.3 Genentech, Inc Tax Reduction Investment Plan, As Amended and Restated
- 15.1 Letter Regarding Unaudited Interim Financial Information.
- 31.1 Certification of Chief Executive Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended
- 31.2 Certification of Chief Financial Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended
- 32.1 Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
Related press release
Genentech similar filings
Filing view
External links